Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Contact Us Sitemap Sign In Register
Link to Homepage About AHAF
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when submission deadlines are announced please click on the link below.

Sign up for new RFP announcements and submission deadline notifications.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research funding through the American Health Assistance Foundation (www.ahaf.org). Please follow instructions on the notification emails for removal requests.

 

Researchers:
Have you heard a story, statistic, or discovery that might interest the public? Let us know about it!

 
AHAF Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

Alzheimer's Disease Research - Current Awards

Dr. Takahisa Kanekiyo

Takahisa Kanekiyo, M.D., Ph.D.

Washington University, School of Medicine
St. Louis, MO

Title: LRP1 In Amyloid Beta Metabolism And CAA
Non-Technical Title: Role Of A Receptor In Amyloid Beta Deposition On Brain Vessels
Duration: April 1, 2009 - March 31, 2011

Mentor:
Guojun Bu, Ph.D.
Washington University

Summary: Mounting pathological studies from Alzheimer’s disease patients have shown that amyloidbeta deposits are found not only in senile plaques but also in cerebral blood vessel as cerebral amyloid angiopathy (CAA), a major cause of intracranial hemorrhage and progressive dementia in elderly population. Amyloid beta deposition in CAA is detected primarily in the smooth muscle layer of cerebral arteries. The low-density lipoprotein receptor-related protein 1 (LRP1), known as amyloidbeta scavenger receptor, is abundantly expressed in smooth muscle cells. Therefore, the specific aims are designed to provide a comprehensive assessment of the function of LRP1 in amyloid beta metabolism and in CAA pathogenesis as well as the effect of amyloid beta on LRP1 expression and function in smooth muscle cells.
More details

Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000



Photo Pending

David Kang, Ph.D.

University of California, San Diego
La Jolla, CA

Title: Novel Domain of LRP Cytoplasmic Tail in APP Processing
Non-Technical Title: Blocking formation of Abeta by inhibitiing APP transport
Duration: April 1, 2007 - March 31, 2011

Summary: We hypothesize that the LRP-C37 domain plays a critical role in transporting LRP and APP to compartments where Ab is normally generated. In this application, we propose to characterize the mechanistic basis of the LRP-C37 domain in LRP and APP transport inside cells and Ab generation. In addition, we will determine the role of the two new LRP-C37 interacting proteins in these processes.
More details

Program: Alzheimer's Disease
Award Type: Standard
$400,000



Photo Pending

Tae-Wan Kim, Ph.D.

Columbia University
New York, NY

Title: Modulation of BACE1 by a Novel Sorting Nexin
Non-Technical Title: BACE1 Trafficking and Alzheimer's Disease
Duration: April 1, 2008 - March 31, 2011

Summary: This study will investigate the mechanism underlying the regulation of BACE1 trafficking and beta-amyloid generation in neurons by a novel sorting nexin. Gaining insight into these cellular mechanisms will lead to development of novel therapeutic approaches for preventing or treating AD.
More details

Program: Alzheimer's Disease
Award Type: Standard
$265,000



Photo Pending

Frank LaFerla, Ph.D.

University of California, Irvine
Irvine, CA

Title: BDNF-mediated treatment for neurodegenerative disease
Non-Technical Title: Stem cells as a treatment option for Alzheimer's disease
Duration: April 1, 2010 - March 31, 2013

Summary: We will explore the therapeutic benefit of using neurotrophins to treat the cognitive decline that characterizes Alzheimer’s disease. We have generated a significant body of preliminary data that show that animal neural stem cells improve function in two mouse models of Alzheimer’s disease, including one with extensive neurodegeneration. The outcome of the proposed studies will test whether neurotrophins, a factor naturally secreted by neural stem cells, can replicate the effects produced by stem cell transplantation. If this is the case, neurotrophin supplementation would provide a very promising pharmacological approach to Alzheimer’s disease that avoids any untoward effects associated with “cell-based therapies”, including stem cell transplants.
More details

Program: Alzheimer's Disease
Award Type: Standard
$400,000



Photo Pending

James Lah, M.D., Ph.D.

Emory University
Atlanta, GA

Title: Targeted Discovery of LR11/SorLA-Based AD Therapeutics
Non-Technical Title: Drug Discovery for Alzheimer's Disease
Duration: April 1, 2007 - March 31, 2010

Summary: We propose to initiate a search for LR11-interacting compounds, which will produce leads in the development of new therapeutic agents. To accomplish this, we will combine our scientific expertise with the capabilities of the NIH-funded Emory Molecular Libraries Screening Center to develop tools to identify and evaluate candidate compounds that interact with LR11.
More details

Program: Alzheimer's Disease
Award Type: Standard
$300,000



Dr. Bruce Lamb

Bruce Lamb, Ph.D.

The Cleveland Clinic Foundation
Cleveland, OH

Title: Microglia , CX3CR1and Alzheimer's Disease Pathogenesis
Non-Technical Title: Activation of the immune system in AD
Duration: April 1, 2007 - March 31, 2011

Summary: The focus of the current proposal is to determine the role of CX3CR1 plays in activation of the immune system, neuronal cell death and Aß deposition in two different mouse models of AD as well as to gain insight into the mechanisms involved. The long-term goal of this project is to gain insight into the role inflammation play in AD and thus provide potential new avenues of therapeutic intervention.
More details

Program: Alzheimer's Disease
Award Type: Standard
$400,000



Dr. Min Jae Lee

Min Jae Lee, Ph.D.

Harvard Medical School
Boston, MA

Title: Role of Usp14 in degradation and aggregation of Tau
Non-Technical Title: Beneficial effects of enhanced degradation of tau proteins through Usp14 inhibition
Duration: April 1, 2010 - March 31, 2012

Mentor:
Daniel Finley, Harvard Medical School

Summary: The goal of this project is to understand the role of Usp14, an endogenous inhibitor of natural protein breakdown machinery, in tau protein degradation and aggregation. Successful results from this project may reveal Usp14 as a novel preventive and therapeutic target for Alzheimer’s disease, whose inhibitors are expected to facilitate the clearance of toxic, aberrant tau aggregates.
More details

Program: Alzheimer's Disease
Award Type: Research Fellowship
$100,000



Dr. Malcolm Leissring

Malcolm Leissring, Ph.D.

Mayo Clinic Jacksonville
Jacksonville, FL

Title: Catabolism Of Amyloid Beta And Tau By Cathepsin D In Vivo
Non-Technical Title: Can Alzheimer Disease Be Treated With The Enzyme Cathepsin D?
Duration: April 1, 2009 - March 31, 2012

Summary: We have discovered that deletion of an enzyme known as cathepsin D (CatD) in mice results in very large and very selective increases in the two toxic protein species that are most closely linked to two characteristics of Alzheimer's disease (AD): (1) the amyloid beta-protein (specifically the 42-amino acid form, amyloid beta42), which deposits in the extracellular "plaques" that characterize AD, and (2) the microtubule-associated protein, tau, which makes up the neurofibrillary tangles that form inside neurons in AD and other diseases. We hypothesize that CatD plays a protective role in preventing AD by (directly or indirectly) breaking down amyloid beta42 and tau. We will test this hypothesis by increasing or decreasing CatD levels in mice that accumulate either amyloid beta 42 or tau.
More details

Program: Alzheimer's Disease
Award Type: Standard
$400,000



Photo Pending

Alan Lerner, M.D.

University Hospitals of Cleveland
Cleveland, OH

Title: Teen IQ, Activity Level, and AD: Mechanisms of the Links
Non-Technical Title:
Duration: April 1, 2006 - June 30, 2010

Summary:
More details

Program: Alzheimer's Disease
Award Type: Pilot
$85,500



Photo Pending

Ling Li, Ph.D.

University of Minnesota
Minneapolis, MN

Title: A Novel Role of ApoA-I in Alzheimer's Disease
Non-Technical Title: Potential Role of a Heart-Protective Protein in Alzheimer's Disease
Duration: April 1, 2010 - March 31, 2012

Summary: Emerging evidence indicates that Alzheimer's disease and cardiovascular disease share common risk factors and pathogenic mechanisms. Human apoA-I is a major cardio-protective protein but its role in the brain pertinent to Alzheimer's disease has not been defined. This study will use a combination of behavioral, biochemical, and electrophysiological approaches to investigate the role of human apoA-I in the development of Alzheimer’s disease-like behavior and neuropathology in a mouse model of Alzheimer's disease.
More details

Program: Alzheimer's Disease
Award Type: Pilot
$150,000



Items 21 - 30 of 65  Previous1234567Next

Last Reviewed On: 07/28/10